Synairgen Regulatory News (SNG)

11 Apr 2006 12:56

Synairgen plc11 April 2006 11 April 2006 SYNAIRGEN PLC Board changes The Board of Synairgen, the drug discovery company focused on identifying andout-licensing new pharmaceutical products which address the underlying causes ofasthma and chronic obstructive pulmonary disease ('COPD'), announces that it hasappointed Dr David Bruce Campbell as a non-executive director with immediateeffect. He replaces David Norwood who has today stepped down from the Board todevote more time to IP2IPO Group plc. Bruce Campbell (61) is currently non-executive Chairman of ProximagenNeuroscience plc, Chief Scientific Officer and a director of IP2IPO Group plc, adirector of Modern Biosciences plc and a non-executive director of iQur Limitedand Proximagen Limited. Formerly, Dr Campbell was Senior VP of International Development at NeurocrineBiosciences, Inc. ('Neurocrine'). Prior to joining Neurocrine, Dr Campbellworked for 27 years at Servier (United Kingdom), latterly as ScientificDirector. In addition, he has also been a director and European Chairman of theDrug Information Association and a member of the European ICH Safety WorkingParty. Dr Campbell is a visiting Professor in Pharmacology at King's College,London. There are no further disclosures to be made in accordance with Schedule 2(g) ofthe AIM Rules. Simon Shaw, Chairman, commented: "We are delighted that Bruce is joining the Board of Synairgen. His extensiveinternational experience in pharmaceutical drug development will be valuable toSynairgen at this exciting time in our development. "On behalf of the Board, I would like to thank David Norwood for his help andguidance as a non-executive director of Synairgen since its formation in late2003." -Ends- For further information, please contact: SynairgenRichard Marsden, Managing Director Tel: 02380 512 800 Hogarth PartnershipMelanie Toyne-Sewell / Georgina Briscoe Tel: 020 7357 9477 This information is provided by RNS The company news service from the London Stock Exchange